Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala
NCT03696303
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
720-777-1084
Adult Trials: 18+ Years
- Age older than 1 month (31 days) and up to 71 months and 28 days.
- Diagnosis of radiologically confirmed pneumonia per WHO criteria in the ED or hospital within 48 hours of hospital admission
- Signed informed consent by parents or legal guardian to participate in the study
- Known immunodeficiency
- Major congenital malformation (e.g., hemodynamically compromised congenital heart
malformation or any malformation leading to recurrent pneumonia) or serious chronic
disorder
- Significant neurological disorder
- Fever or suspicion of community-acquired pneumonia or other respiratory infectious
disease (symptoms of cough, congestion, tachypnea, indrawing, etc.)
- Hospitalization within the previous 30 days for pneumonia or respiratory infection
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Cuilapa, Santa Rosa
- Guatemala,
- Guatemala,
| Descriptive Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Brief Title | Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala | ||||||||
| Official Title | Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala | ||||||||
| Brief Summary | This prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of age or younger in Guatemala. | ||||||||
| Detailed Description | Not Provided | ||||||||
| Study Type | Observational | ||||||||
| Study Design | Observational Model: Case-Control Time Perspective: Prospective | ||||||||
| Target Follow-Up Duration | Not Provided | ||||||||
| Biospecimen | Retention: Samples With DNA Description: Urine Blood Nasopharyngeal swab samples | ||||||||
| Sampling Method | Non-Probability Sample | ||||||||
| Study Population | Children 5 years of age or younger with either community-acquired pneumonia (cases) or health children (controls). | ||||||||
| Condition |
| ||||||||
| Intervention | Other: Urinary antigen detection assay
Screening for Ag level in S. pneumoniae urinary antigen detection assay. | ||||||||
| Study Groups/Cohorts |
| ||||||||
| Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||||
| Recruitment Information | |||||||||
| Recruitment Status | Recruiting | ||||||||
| Estimated Enrollment | 960 | ||||||||
| Original Estimated Enrollment | Same as current | ||||||||
| Estimated Study Completion Date | June 30, 2020 | ||||||||
| Estimated Primary Completion Date | April 30, 2020 (Final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria | CASES: Inclusion Criteria:
Exclusion Criteria:
CONTROLS: Inclusion Criteria:
Exclusion Criteria:
| ||||||||
| Sex/Gender |
| ||||||||
| Ages | 31 Days to 5 Years (Child) | ||||||||
| Accepts Healthy Volunteers | Yes | ||||||||
| Contacts |
| ||||||||
| Listed Location Countries | Guatemala | ||||||||
| Removed Location Countries | |||||||||
| Administrative Information | |||||||||
| NCT Number | NCT03696303 | ||||||||
| Other Study ID Numbers | 18-0737 | ||||||||
| Has Data Monitoring Committee | No | ||||||||
| U.S. FDA-regulated Product |
| ||||||||
| IPD Sharing Statement |
| ||||||||
| Responsible Party | University of Colorado, Denver | ||||||||
| Study Sponsor | University of Colorado, Denver | ||||||||
| Collaborators | Pfizer | ||||||||
| Investigators |
| ||||||||
| PRS Account | University of Colorado, Denver | ||||||||
| Verification Date | September 2019 | ||||||||